The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

U.S. futures for the S&P 500 were up 0.1% and futures for the Dow Jones Industrial Average rose 0.2%. Changes in futures do not necessarily predict movements after the opening bell.

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

Finance News; Setback for GSK as Blenrep does not win US FDA committee support; Setback for GSK as Blenrep does not win US FDA committee support ...